CAMBRIDGE, Mass. & BEDMINSTER, N.J.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, and TYME Technologies, Inc.

Kia Syros has received a new HTK (EX) trim, which commands ₹50,000 over its immediate lower trim HTK (O). Also, it comes with ...

The Kia Syros HTK (EX) variant finally makes its entry, making it one of the most value-for-money offerings in the Syros' ...

The HTK (EX) is positioned above the HTK(O) and brings several design and convenience upgrades. With this addition, the Syros ...

After the Carens Clavis, Kia has introduced an HTK (EX) variant for the Syros, which brings some cosmetic additions over the ...

Kia India reported it highest ever December sales in the past month at 18,659 units taking its market share up from 2.8% to 4 ...

Kia Syros is now available in a new feature-loaded HTK (EX) variant. It is available in petrol and diesel versions, priced at ...

Shares of Syros Pharmaceuticals (NASDAQ: SYRS) fell more than 26% today after the development-stage company announced the pricing of a stock offering. The business will sell roughly 8.7 million shares ...

Kia India has updated the variant lineup of its Syros and the Carens Clavis for the Indian market. According to a statement, ...

The HTK (EX) trim is priced at ₹9.89 lakh (ex-showroom) for the petrol version and ₹10.63 lakh for the diesel, placing it ...

Kia India launches the Syros HTK(EX) variant at ₹9.89 lakh with sunroof, 12.3-inch touchscreen, six airbags and petrol-diesel ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that it has entered into a ...